CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 193 enrolled
Drug / intervention
Spiriva Respimatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03188120
NCT03188120N/ACompleted

Specific Use-Result Surveillance of Spiriva Respimat in Asthmatics (Patients With Mild and Moderate Persistent Asthma)

Boehringer Ingelheim·observational·Posted Jun 15, 2017·Updated Nov 27, 2019

In Brief

An observational study evaluating Spiriva Respimat for Asthma. Completed, enrolled 193 participants across 1 site.

Detailed Summary

The study objective is to investigate the safety and effectiveness of Spiriva Respimat in patients with mild to moderate persistent asthma under real-world use

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedJun 15, 2017
Enrollment StartJul 4, 2017
Primary CompletionSep 22, 2018
Study CompletionNov 8, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.0 years ago

Interventions

Spiriva Respimatdrug

Drug